SAGE Therapeutics Inc SAGE Stock Quotes and Insider News

Insider Chart Past 6 Months

Technical Chart

Filings by transaction date

Apr 18, 2018 (filed on Apr 19, 2018)

Insider Name:

Starr Kevin P

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-24,000

Price:

$168.28
Apr 17, 2018 (filed on Apr 19, 2018)

Insider Name:

Starr Kevin P

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-35,000

Price:

$169.25
Apr 02, 2018 (filed on Apr 04, 2018)

Insider Name:

Cloonan Michael

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

36,000

Price:

--
Apr 02, 2018 (filed on Apr 04, 2018)

Insider Name:

Iguchi Kimi

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

31,500

Price:

--
Apr 02, 2018 (filed on Apr 04, 2018)

Insider Name:

Cook Anne Marie

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

31,500

Price:

--
Apr 02, 2018 (filed on Apr 04, 2018)

Insider Name:

Robichaud Albert

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

31,500

Price:

--
Apr 02, 2018 (filed on Apr 04, 2018)

Insider Name:

Kanes Stephen

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

27,000

Price:

--
Apr 02, 2018 (filed on Apr 04, 2018)

Insider Name:

Jonas Jeffrey M

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

90,000

Price:

--
Mar 06, 2018 (filed on Mar 08, 2018)

Insider Name:

Paul Steven M

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-58,139

Price:

$172.00
Feb 16, 2018 (filed on Feb 20, 2018)

Insider Name:

Starr Kevin P

Ownership Type:

Indirect Ownership

Securities:

Common Stock

Nature of Transaction:

J - Other transaction

# or value acquired/disposed of:

-510,554

Price:

--

Filings by filing date

Apr 18, 2018 (filed on Apr 19, 2018)

Insider Name:

Starr Kevin P

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-24,000

Price:

$168.28
Apr 17, 2018 (filed on Apr 19, 2018)

Insider Name:

Starr Kevin P

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-35,000

Price:

$169.25
Apr 02, 2018 (filed on Apr 04, 2018)

Insider Name:

Cloonan Michael

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

36,000

Price:

--
Apr 02, 2018 (filed on Apr 04, 2018)

Insider Name:

Iguchi Kimi

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

31,500

Price:

--
Apr 02, 2018 (filed on Apr 04, 2018)

Insider Name:

Cook Anne Marie

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

31,500

Price:

--
Apr 02, 2018 (filed on Apr 04, 2018)

Insider Name:

Robichaud Albert

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

31,500

Price:

--
Apr 02, 2018 (filed on Apr 04, 2018)

Insider Name:

Kanes Stephen

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

27,000

Price:

--
Apr 02, 2018 (filed on Apr 04, 2018)

Insider Name:

Jonas Jeffrey M

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

90,000

Price:

--
Mar 06, 2018 (filed on Mar 08, 2018)

Insider Name:

Paul Steven M

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-58,139

Price:

$172.00
Feb 16, 2018 (filed on Feb 20, 2018)

Insider Name:

Starr Kevin P

Ownership Type:

Indirect Ownership

Securities:

Common Stock

Nature of Transaction:

J - Other transaction

# or value acquired/disposed of:

-510,554

Price:

--

News

Biz Brief

Sector: Healthcare	Industry: Biotechnology & Medical Research

See Regulatory Filings on SEC

Company Contact

Address:	215 1st St CAMBRIDGE MA 02142-1213
Tel:	N/A
Website:	www.sagerx.com
IR:	See website

Key People

Kevin P. Starr Independent Chairman of the Board	Thomas D. Anderson Chief Commercial Strategy Officer	Jeffrey M. Jonas President, Chief Executive Officer, Director
Kimi E. Iguchi Chief Financial Officer, Treasurer	Anne Marie Cook Senior Vice President, General Counsel	Amy Schacterle Senior Vice President - Regulatory Affairs and Quality Assurance
Christopher Silber Senior Vice President - Clinical Development	Albert J. Robichaud Chief Scientific Officer	Frank Sanders Vice President of Sales and Marketing
Paul Hodgkins Vice President - Health Economics and Outcomes Research and Value Demonstration

Business Overview

SAGE Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company's lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor. The Company's next-generation product candidates, SAGE-217 and SAGE-689, also target the GABAA receptor system. The Company is focused on developing drugs based on selective allosteric modulation of CNS synaptic and extrasynaptic receptors. The Company's chemistry platform is focused on the chemical scaffolds of endogenous or chemically modified synthetic neuroactive steroid compounds that are allosteric modulators of GABAA or N-Methyl-D-aspartic acid or N-Methyl-D-aspartate (NMDA) receptors.

Financial Overview

For the fiscal year ended 31 December 2017, SAGE Therapeutics Inc revenues was not reported. Net loss increased 70% to $270.1M. Higher net loss reflects R & D exp increase of 74% to $190.4M (expense), General & admi increase of 71% to $47.2M (expense), Stock-based Compensation in R&D increase of 78% to $19.9M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$4.75 to -$7.09.

Employees:	257 as of Dec 31, 2017

Reporting Currency:	U.S. Dollars
Enterprise value:	$6,257M as of Dec 31, 2017
Annual revenue (TTM):	$0.00M as of Dec 31, 2017
EBITDA (TTM):	-$272.63M as of Dec 31, 2017
Net annual income (TTM):	-$270.12M as of Dec 31, 2017
Free cash flow (TTM):	-$220.64M as of Dec 31, 2017
Net Debt Last Fiscal Year:	N/A
Shares outstanding:	45,777,940 as of Feb 15, 2018
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization